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Abstract: The incidence of neglected diseases in tropical countries, such as Leishmaniasis and 
Chagas’s disease, is attributed to a set of biological and ecological factors associated with the 
socioeconomic context of developing countries and with a significant burden to health care 
systems. Both Leishmaniasis and Chagas’s disease are caused by different protozoa and develop 
diverse symptoms, which depend on the specific species infecting man. Currently available 
drugs to treat these disorders have limited therapeutic outcomes, frequently due to 
microorganisms’ drug resistance. In recent years, significant efforts have been made towards 
the development of innovative drug delivery systems aiming to improve bioavailability and 
pharmacokinetic profiles of classical drug therapy. This paper discusses the key facts of 
Leishmaniasis and Chagas’s disease, the currently available pharmacological therapies and the 
new drug delivery systems for conventional drugs. 
Keywords: Neglected diseases; drug delivery systems; antiprotozoal agents; Chagas’s disease; 
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1. Introduction 
In recent decades, the medical and pharmaceutical fields have been offering breakthrough 
solutions to drug delivery problems by nanotechnological innovations. However, the world still 
faces the demand for improved solutions to deal with spreadable pathologies, commonly referred 
to as neglected diseases (NDs). The latter are defined as a group of infections of bacterial, 
parasitic, protozoan, helminthic and viral origin, essentially affecting tropical countries, 
economically unfavorable, and where NDs are endemic. Most of these infections are caused by 
protozoa, for which transmission is carried out by means of vectors. Therapeutic solutions still 
rely on a small range of products, mostly chemically unstable or obsolete [1,2].  
NDs are a result of biological and ecological circumstances, commonly associated with 
adverse socioeconomic conditions and with low development of affected countries worldwide 
[3].  
Owing to the trends of the pharmaceutical industry in pursuing more profitable markets, 
these illnesses represent a great concern of health care systems [2,4]. The impact of NDs is huge 
as they are estimated to cause an average loss of 534,000 lives every year, leading to an economic 
cargo of billions of dollars annually. The overall occurrence of these pathologies is enhanced by 
the deprivation of authorized vaccines, thereby requiring the need for more reliable and infallible 
drugs to be used in their treatment. In addition, where the access to medication is possible, its 
effective use is becoming further restricted due to parasite resistance [5]. To overcome this 
limitation, efforts have been made to develop new therapeutic approaches [6]. Despite the 
number of currently ongoing governmental health programs to target these pathologies, the 
successful rate in their eradication is still below expectations. Table 1 lists the 13 most common 
tropical NDs [7–9].  
Different regions worldwide are affected by different parasites, resulting in the need for 
more effective drugs. Still, the impact of economic investments to treat the affected populations 
along with the reduced expectation of economic return to the pharmaceutical industries are 
reasons for the limited research developments in this field.  
In the last 30 years, less than 1% of all new drugs were intended for the treatment of tropical 
diseases. As they are not therapeutic priorities, the capitals which could be targeted to the 
treatment of NDs have been applied to others of lower incidence, but with direct (economic) 
impact in, e.g., North America and Europe [10,11]. 
Given this scenario, some pharmaceutical companies have extended their portfolio on 
research and development of medicines into the sector of parasitic diseases, but not without 
previous identification of some goals, namely, reduced manufacturing price, high oral 
bioavailability, tolerability of adverse effects, possibility of co-administration with other drugs, 
efficacy at lower doses, potential recovery in both acute and chronic phases, and absence of 
mandatory hospitalization for the administration of these medicines [12]. 
NDs are conditions that, together with their predominance in contexts of poverty, still 
cooperate to survive the panorama of disparity, since they show strong obstacles against the 
development of targeted countries. 
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Table 1. Description of the top 13 neglected diseases (NDs) according to their prevalence. 
Pathology 
World Prevalence 
(in Millions) 
Risk Population 
(in Millions) Prevalence Regions 
Ascariasis 807 4200 
South and East Asia, Pacific Islands, Africa 
Sub-Saharan Africa, India, China, Latin America and the Caribbean 
Trichuriasis 604 3200 
South and East Asia, Pacific Islands, Africa 
Sub-Saharan Africa, India, Latin America and the Caribbean 
Ancylostomiasis 576 3200 
South and East Asia, Pacific Islands, Africa 
Sub-Saharan Africa, India, Latin America and the Caribbean 
Schistosomiasis 207 779 Sub-Saharan Africa, Latin America and the Caribbean 
Filariasis 120 1300 
South and East Asia, Pacific Islands, Africa 
Sub-Saharan Africa 
Trachoma 84 590 Middle East and North Africa, Sub-Saharan Africa 
Onchocerciasis 37 90 Sub-Saharan Africa, Latin America and the Caribbean 
Leishmaniasis 12 350 
South Asia, Sub-Saharan Africa, India, America 
Latin America and the Caribbean 
Chagas’s Disease 8–9 25 Latin America and the Caribbean 
Hansen’s Disease 0.4 - Sub-Saharan Africa, India, Latin America and the Caribbean 
African Trypanosomiasis 0.3 60 Sub-Saharan Africa 
Dracunculiasis 0.01 - Sub-Saharan Africa 
Buruli ulcer - - Sub-Saharan Africa 
The present review discusses the formulation approaches currently being employed in the 
management of two important neglected diseases, namely, Leishmaniasis (LM) and Chagas’s 
disease (CD). It also discusses the classical drugs used for the treatment of these diseases, along 
with the pharmacological combinations available. An insight into the use of natural drugs has 
also been provided, followed by novel formulation strategies to incorporate classical drugs into 
new drug delivery systems (DDS). This review further discusses the role of contemporary 
formulations in improving the pharmacokinetic profile of the available drugs and to enhance 
their therapeutic performance [13].  
2. Key facts of neglected diseases: Leishmaniasis and Chagas’s disease 
According to the WHO’s classification, neglected diseases are divided into two categories: i) 
Preventive chemotherapy and transmission control (PCT), and ii) Innovative and intensified 
disease management (IDM). While the former is controlled by administering safe, effective and 
cost-effective drugs from time to time to vulnerable populations, the latter stands out as a 
considerable challenge and call for more focused efforts for generating innovative tools to control 
these diseases. These categories have also been referred to as ‘tool ready’ and ‘tool deficient’, 
respectively. LM and CD fall under the second category, not only by finding places in the list of 
the twenty NDs released by WHO, but also because they form a part of the Centre for Disease 
Control and Prevention plan of action. In 2012, the London declaration on NDs brought forth the 
goal of eradicating 10 of these destructive illnesses until 2020. It also highlighted the need to 
expand the eradication programs to avoid the spreading of the diseases and to cooperate in the 
field of research and development, aiming to create new therapeutic tools capable to destroy the 
parasites that are the origin of these epidemies [14–16].  
According to the WHO’s reports, 700,000 to 1 million new cases of LM are recorded yearly, 
whereas 26,000 to 65,000 mortalities occur [17]. On the other hand, 6 to 7 million people are 
reported to be infected by CD globally [18]. Although CD is endemic in Latin America, it has been 
spreading to other countries (also identified as developed countries) by means of migration of 
the vector responsible for the disease transmission. The measures applied to control the 
dispersion include extensive actions to control the vector proliferation. Despite this, the need for 
vaccine development and discovery of novel antiprotozoal agents cannot be over emphasized. 
The dearth of pediatric formulations is another cause of concern [2]. Indeed, visceral LM and CD 
have been listed among NDs that have the highest mortality rate, while the drugs/formulations 
aimed to treat them are inadequate. The current strategy to manage NDs incorporates one or a 
combination of the following approaches: i) preventive chemotherapeutic measures; ii) intensive 
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case management; iii) vector control procedures; iv) veterinary health; and v) innocuous water, 
correct sanitation and good hygiene habits [19]. 
3. The diseases at a glance 
LM is a chronic pathology triggered by an intracellular protozoan belonging to the 
Leishmania family. It affects a high number of individuals worldwide and is endemic in several 
countries. In some developing countries, LM is a critical collective health problem. The disease is 
also endemic in southern Europe, with people moving to these regions being more likely to be 
infected. Due to a progressive occurrence of this illness, its relevance has expanded immensely. 
This increased incidence is, to some extent, associated with emigrants, displacements, war, 
housing in new regions, inadequate surveillance standards in some countries, and other 
situations that have contributed to an increase in cases of LM worldwide. There are several types 
of Leishmania, recognized according to the clinical manifestations they produce. Four are the 
outcome models of this disease: cutaneous LM (CL), which reaches the surface of the skin; 
mucocutaneous LM (MCL), affecting the surface of the skin and mucous membranes; diffuse 
cutaneous LM (DCL); and visceral LM (VL), which affects organs of the mononuclear phagocytic 
system [20]. The disease is transmitted by the bite of a phlebotomine insect—the vector. During 
the adult phase, this insect naturally adapts to a variety of environments and when it is in the 
larval phase, it grows in humid terrestrial milieus—with reduced clarity and abundant organic 
material. Dogs, marsupials and foxes are the natural reservoirs of the disease. The potential of 
these animals as a source of VL infection is, however, a subject of discussion. Nonetheless, there 
is no transmission from person-to-person, nor from animal-to-animal.  
In Portugal, as an example of a Southern European country, LM is a zoonosis caused by the 
parasite Leishmania infantum and the dog is the main host and the primary reservoir regarding 
the human visceral infection. The species of the vector are the Phlebotomus perniciosus and the 
Phlebotomus ariasi. Subtle changes in climate, as increasing temperatures, may lead to the 
exacerbation of the disease, spreading in both animals and humans, and increasing the prevalence 
of the pathology. Portugal has a predominance of LM in children, although this trend has been 
decreasing. Nevertheless, a marked increase in adults with human immunodeficiency virus 
/acquired immunodeficiency syndrome (HIV/AIDS) is significant. Although CL has a small 
incidence in Portugal, it is estimated that approximately 10 new cases are diagnosed each year. 
Moreover, canine LM has increased by approximately 20% in endemic areas (namely, great 
Lisbon and Algarve) [21–23]. 
CL is expressed in the human organism as an ulcer and usually heals on its own and 
generates a small scar [24]. The DCL is more complex, producing lesions that diffuse along the 
skin and with less capacity for recovery [25]. In the case of MCL type, skin wounds initially 
develop and may spread to the mucous membranes of the face; if inflammation occurs, it can 
particularly lead to erosion of the nasal cavities and the oral cavity [22]. In VL, skin lesions take 
approximately 2 to 8 months to propagate in parallel with severe inflammation responsible for 
lesions in liver and spleen, which can even lead to death if untreated [26]. Microscopic 
identification of parasites, predominantly the detection of amastigotes in tissue samples, 
polymerase chain reaction (PCR), serological tests, and immunofluorescence, among others, is of 
paramount importance [27]. 
CD, of which the etiologic agent is Trypanosoma cruzi, is one of the most important widely 
propagated NDs. CD is usually transmitted by means of vectors, responsible for approximately 
80% of the contagious events, and occurs by the contact of humans with contaminated excrements 
of the insect Triatoma—the vector. This latter is infected after nourishing itself with some host 
present in the environment, further enabling the spread of the disease to another mammal, 
including man. The transfusion of blood, blood products by themselves or transplacental 
infection are other routes of spreading the disease, at any stage of development. However, the 
contamination of blood supply has so far not been the predominant form. Nowadays, the 
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ingestion of food infected with Trypanossoma cruzi is the principal route of dissemination of this 
disease to humans. Oral transmission of CD has also unexpectedly emerged in non-endemic 
regions, where the vector appeared to be under control, due to food exposure to triatomine feces. 
Micro-epidemics occur according to this modus operandi, leading to critical public health 
situations [28,29]. 
After entry into the host, parasites infect the host cells and differentiate into reproductive 
amastigote forms. The acute phase of infection comprehends inflammatory reactions and 
common symptoms, such as fever and facial edema (which is common, particularly around the 
eyes). A rather extensive and asymptomatic period can follow, during which the detection of 
parasites is quite laborious. This stage can last for 10 years. In specific circumstances, a growing 
inflammatory lesion may occur as a reaction to residual parasites, sometimes fatal to the heart, 
esophagus, colon and other organs. Together with the symptomatic diagnosis and acute phase 
microscopy (while it is possible to locate trypomastigotes in the blood), the serological diagnosis 
of Trypanossoma cruzi antigen is usually performed to detect antibodies. PCR techniques, clinical 
trials, surveillance studies, xenodiagnosis and blood cultures may also be performed [30,31]. 
4. Pharmacological interventions 
4.1. Traditional pharmacological approaches 
LM and CD are examples of NDs subjected to a reduced attention by the government and 
the pharmaceutical industry. In the last 15 years, the global pipeline of antiparasitic medicines 
was reduced down to 0.1% of the employed universal capital [32,33]. These two pathological 
conditions have similar parasite taxonomical origin, morphology and biochemical characteristics. 
The medicines currently used in the treatment of LM and CD have marked toxicity, inconstant 
effectiveness and require formalities for management or compliance with parenteral therapy 
regulations. CD has few drugs or treatments in clinical evolution. In contrast, for LM, there has 
been considerable progress with liposomal AmB (AmBisome®), miltefosine and paromomycin 
[34]. 
Nonetheless, research has so far been mostly inconclusive. It is critical to emphasize four 
particularities on the biology of Leishmania, especially on the activity of drugs: 
• the intracellular location of the amastigote form; 
• the distinct pharmacokinetic requirements to transport active substances in liver, spleen, 
bone marrow (on VL) or skin (on CL); 
• the significant variations in drug susceptibility of the 17 genera of Leishmania responsible 
for LM in humans; 
• the effect of immunosuppression linked to LM, which may reduce the efficacy of certain 
drugs. 
The absence of a human vaccine against LM endorses chemotherapy as an election 
procedure in the treatment of LM and CD. Although there are several available 
chemotherapeutics against human LM, much of them rely on new formulations of old drugs [35]. 
The drug of election to handle all forms of LM has so far been pentavalent antimony. A wide 
range of LM patients in India, for instance, currently have a high degree of resistance to 
pentavalent antimony. Despite this, the therapeutic usefulness is kept in other areas of the world 
but with restricted license given the long treatment durability, the parenteral administration 
inevitability and the description of markedly mortal toxic effects (namely for the heart, liver and 
kidneys). In parallel with VL, some approaches are also restricted in the therapeutic of CL [36]. 
In the English-speaking states, the commercially available formulation is sodium stibogluconate 
(Pentostam®), whereas in France, Spain and Portugal, the therapeutic agent used is N-
methylglucamine antimoniate (Glucantime®). Despite successive failures in therapy with 
pentavalent antimony, both medicines ((Pentostam® and Glucantime®) have so far remained as 
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the first-line drugs against all types of LM (despite several therapeutic failures with pentavalent 
antimony) due to their valuable effect at a lower price compared to second-line drugs [37,38]. 
AmB is a polyene antibiotic used as an antifungal, with a high action against promastigotes 
and amastigotes. This drug is used as a second option, since it presents several adverse reactions 
and, therefore, should only be used when antimony treatment is not effective. In India, this drug 
is the current therapy of choice, since pentavalent antimony has ceased to reveal activity [39]. 
AmB heads the therapeutic arsenal for the treatment of VL in a sequence of lipid-based 
formulations for the therapy of systemic mycoses in immunocompromised patients [40]. Of the 
suitable treatment for VL, only the liposomal formulation AmBisome® is patented for VL and 
only in some parts of the world. After negotiations with the manufacturers, the cost of this 
product decreased, but several ampoules are still vital for single-course treatment and their 
stability in a small range of temperatures is controversial, as well as the potential risk of adverse 
reactions. Therefore, universal use of AmBisome® for VL requires an extensive analysis in 
confined regions of the world [41,42]. 
Pentamidine is an aromatic diamine with marked activity as a substitute to antimony 
therapy. However, due to its intrinsic toxicity, its use is quite limited [43]. In previous years, the 
aminoglycoside paromomycin exhibited leishmanicidal effect. Later, some trials were very 
successful with this therapy and had the benefit of a reduced price in the market. Despite this, 
according to different healing responses in distinct locations, it is not used nowadays in 
monotherapy due to several inconclusiveness in published clinical literature [43]. In contrast, 
miltefosine was the primary oral treatment for VL with leishmanicidal effect. This substance has 
a 94% activity and the antiparasitic was exclusively subjected to phase-IV tests. Nevertheless, 
certain concerns on its application are raised, namely, the risk of malformations in the embryo, 
possible relapses after 28 days of treatment and limited patient cooperation, requiring additional 
care according to the drug resistance profile [44]. 
Sitamaquine (chemically, 8-aminoquinoin) is the single therapeutic agent designed for the 
treatment of VL and can be administrated orally, which is a considerable advantage for patient 
compliance. However, despite its relevant therapeutic effect, some adverse reactions have been 
reported, being vomiting, dyspepsia, cyanosis and nephrotic syndrome the most prominent. The 
mechanism of action of this drug is associated with the inhibition of the mobility, structure and 
development of the parasite. Nevertheless, more trials are still needed to understand the overall 
pharmacokinetics and pharmacodynamics of this drug [45,46]. Triazole and imidazole drugs, 
known as antifungal agents, also exhibit activity against some Leishmania species. They are 
however limited for subsequent trials due to their low water solubility [47]. 
Medicines currently applied in the treatment of VL and TL, such as Pentostam®, 
Glucantime®, pentamidine and amphotericin B, have no therapeutic effects if administered orally 
and require long-term parenteral administration. Additionally, these chemotherapeutic agents 
are expensive and have marked toxicity. Together, all these aspects lead to the minimal 
compliance or even withdrawal of patients from therapy. On the other hand, if the therapy is 
interrupted, it will impact enormously on the disease spread and on the appearance of drug 
resistant strains [48,49]. 
CD, a pathology identified over 100 years ago, has a long chronicle of successive efforts to 
therapeutically control its progress. Among these, compounds with questionable outcomes are 
listed, such as gentian violet (used as prophylactic in blood banks), nifurtimox (NF) and 
benznidazole (BNZ) [50,51]. NF and BNZ exhibit strong activity with some variability depending 
on the strain of the pathogen to be eliminated, the difference in sensitivity to treatment between 
patients (affected by age and geographical location), the clinical phase of the disease when these 
drugs are administered (with maximal effectiveness of both in the acute phase), dose, course of 
treatment, and side effects (such as weight loss, drowsiness, excitement) [52]. NF is a trypanocide 
drug, acting not only against circulating trypomastigotes but also against amastigotes. Even 
though it was forbidden for extended periods of time in clinical therapy, its use was increased 
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after suspending the therapy with BNZ. Trypanocide activity, with a half-life in plasma of 
approximately 3 hours, was reduced thereby requiring continuous administration. The most 
frequent adverse effects impair the central (CNS) and peripheral nervous system (PNS), with 
gastrointestinal (GI) manifestations, such as nausea, vomiting, stomach pain and diarrhea [53]. 
BNZ exhibits activity against various Trypanossoma cruzi strains. It is given orally in adolescents. 
A recent formulation for pediatric administration has been proposed [54]. Adverse reactions have 
also been commonly reported, particularly hypersensitivity skin responses, bowel and neurologic 
manifestations. This therapeutic agent acts by three different mechanisms: trypanocidal effect, 
increased phagocytosis and parasite lysis by an IFN-Ɣ-dependent mechanism, and the inhibition 
of parasite growth by NADH-fumarate reductase blockage [12].  
Due to the amplitude of these reactions, treatments with NF were forbidden in some 
southern countries. The reduction in the activity of (mono)therapy against Trypanossoma cruzi, 
combined with the inadequacy and considerable low income of workers in the countries affected 
by CD, highlights the need for new therapeutic agents. Other drugs act in vitro against 
Trypanossoma cruzi but, at present, only these two (BNZ and NF) are applied in human therapy. 
Adverse effects have a higher incidence in individuals over 50 years old, but the administration 
of these drugs is not advised in patients within this age range. The World Health Organization 
(WHO) provides these medicines free of charges. Both drugs are administered orally using a 
follow-up method to monitor patients and their administration is strictly forbidden during 
pregnancy, and conditions of hepatic and renal failure. Comparative trials have so far not been 
performed and, therefore, it is unknown to which one of the two drugs the adults infected with 
Trypanossoma cruzi present greater tolerance [55]. Some studies argue the formation of free 
radicals and/or electrolyte metabolites to explain the NF and BNZ mechanisms of action [56]. 
4.2. Pharmacological combinations 
The combination of drugs to treat LM has become a gradual procedure adopted because of 
the progressive absence of viable results with single-drug regimens. Therapeutic associations in 
VL bring several advantages. Indeed, the association of drugs belonging to different chemical 
groups allows the reduction in the time of treatment and in the integral amount of drug 
employed, which, in turn, leads to the reduction of toxicity, enhanced compliance and reduced 
individual burden. Additionally, the cost of the therapy is also reduced. Drug resistance is 
another problem that generates gaps in the treatment [57–59]. Parasite resistance to miltefosine 
due to mutations has also been studied, but the administration of this drug in VL has been 
reported for a limited period. Thus, combined therapy can contribute to delaying drug resistance 
and increase the half-life of drugs [60,61].  
Such combinations can even optimize therapeutic efficacy in HIV-infected patients in whom 
monotherapy treatment has not been effective. Several assays have shown an increase in the 
leishmanicidal activity in a certain combination of drugs [62].  
A formulation of paromomycin with sodium stibogluconate in VL treatment with positive 
responses in Sudan was evaluated [63]. The association of oral allopurinol with intravenous 
Pentostam® was also applied against VL in Kenya. Although the therapy was initially successful, 
some redress occurred later. A study comparing a combination of allopurinol and antimony, with 
these two drugs separately, was carried out in the treatment of canine LM. The results showed 
that combined therapy of the two drugs offered better response than each one separately. 
Allopurinol was shown to inhibit CL expansion, but only when used as an adjuvant to 
pentavalent antimony. The combined treatment condensed the course of antimony therapy and 
long-term administration of allopurinol was satisfactorily accepted [64]. These results support 
combined chemotherapy as a viable solution in the treatment of CL. However, the responses are 
still very inconclusive and require additional clinical studies. 
Imiquimod is an imidazoquinoline which, together with meglumine antimoniate, is an 
excellent alternative for the treatment of CL [65]. Nevertheless, a large part of the reported results 
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is obtained from a small number of patients. Thus, more trials are needed to strengthen 
conclusions [66]. Another study assessed the lack of available combinations of drugs for VL, 
although coadministration of some leishmanicidal drugs was evaluated through experimental 
and preclinical toxicokinetic analyses however with no tangible results. Some trials demonstrated 
that a combination of AmBisome® with paramomicin or miltefosine, as well as miltefosine with 
paromomycin, reduced the cost of treatment and was successful in the restraint of the pathology 
[40,67]. 
In CL, it was verified that azole antifungals, such as fluconazole and itraconazole, have some 
therapeutic effect. Further studies of adjuvant therapy with immunomodulators with recovery 
capacity, and a combination of bacillus Calmette-Guérin and antimony, were also performed. 
Here, once more, the combination of antimony plus another drug exhibited increased activity 
compared to each drug isolated [68].  
All the studies carried out so far on CD revealed that an infallible pharmacological treatment 
was not yet achieved, especially for the chronic phase of the disease. Thus, one of the most 
beneficial options in CD therapeutics is combination therapy, especially the synergism between 
BNZ and other azole derivatives, such as itraconazole [69]. Nitric oxide administered together 
with BNZ has also been useful in preventing death through the reduction of parasitemia and 
inflammation in the heart [70]. 
4.3. New drugs 
The design of new drugs for CD is mainly hampered because patients who enter in an 
undetermined phase of disease development do not express symptoms and there is an enormous 
complexity to identify parasites. Despite this, several drugs are found in medical studies for this 
pathology. Inhibitors of lanosterol, notably posoconazole and E1224, have proved very 
promising. Both are available orally and are in the preliminary testing phase [69,71,72]. The 
cysteine- protease inhibitor has also shown activity in prototypes of chronic rodents and is in pre-
clinical development. To avoid the marked adverse reactions of NF and BNZ used in CD, as well 
as the lack of pediatric formulation and its reduced activity in eliminating the parasite, clinical 
trials with antifungal triazoles (ravuconazol, voriconazole) are being carried out [73–76]. Yet, 
certain antifungals, such as ketoconazole and itraconazole, are not capable of inducing a complete 
parasitological recovery of this disease [77,78]. Posoconazole showed a promising response in the 
treatment of patients in both chronic and acute phases, especially in BNZ resistant strains, and is 
currently the candidate of choice. The most relevant benefits are mainly its marked activity and 
selectivity, therapeutic effect against resistant strains, greater tolerance and safety profile. The 
most significant constraints are the high associated amounts and high manufacturing costs 
[71,79]. 
The discovery of nitroreductase in Trypanossoma cruzi underlies the idea that the compounds 
have the potential to be activated by parasites rather than by host cells, reducing adverse 
reactions, and the ability to occur mutations, a concern associated with these compounds [80,81]. 
Regarding LM, and although VL is a lethal disease, no human vaccine that can be used has 
yet been developed, and the ones under development are directed to the less critical configuration 
of the pathology, which is the cutaneous form. Investigating self-resolving infections or 
spontaneously immune people provides important insight into the possible manufacture of these 
vaccines [82,83]. 
The immunization against Leishmania encompasses the inoculation with the species of 
parasites in a covered area to avoid the appearance of lesions in exposed regions of the body. 
However, some analyses have indicated a poorly effective defense against VL and a low 
probability of immunity to other vaccines [84,85]. Another assay was performed with 
leishmanolysin, a relevant virulence agent that could be employed as a vaccine against LM. As 
such, it has been observed that gp63 is the richest glycoprotein in Leishmania. Moreover, gp63 is 
linked to the defense against lysis caused by the complement system. Published studies ensure 
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that this glycoprotein can activate cytokines involved in the Th1 response. In immunology, a 
vaccine should induce the Th1 response and reduce immunosuppressive conditions. Given this, 
it is estimated that gp63 or leishmanolysin is a relevant virulence factor in CD and is therefore a 
suitable candidate for vaccine design [86–88]. 
Drugs, such as pentamidine, have been used for a few dozen years in these two diseases. 
However, studies conducted to identify other therapeutic agents demonstrated a linkage with 
improved pharmacological and safety attributes than with pentamidine. Arylimidamide 
(DB766), given orally to rats, exhibited benefits against resistant strains, although with a narrow 
therapeutic window [89]. In another in vivo study using mice, the results revealed improved 
benefits with DB613A, which exhibited clinical effectiveness with half of the maximal inhibitory 
concentration in amastigote forms [90]. 
4.4. Herbal Treatments 
Since ancient times, herbal, animal and mineral compounds have been used in classical 
medicine against human diseases. For centuries, these approaches have been the only available 
approaches to treat human diseases [91]. Today, in underdeveloped countries, approximately 
80% of individuals are almost entirely dependent on this “natural medicine” approach to address 
their basic health needs [92]. Natural substances and/or extracts have received the attention of the 
pharmaceutical industry worldwide to develop new formulations with a potential therapeutic 
effect. Among the most analyzed natural substances, extracts of plants predominate in the origin 
of constituents with leishmanicidal effect [93]. Drugs identified from natural sources have been 
listed by numerous laboratories worldwide. 
The main advantages of phytocomposites include the protection against toxic effects, the 
enhancement of the therapeutic effect, increased safety, increasing retention time, and defense 
against physical and chemical degradation [94].  
Several plants were found to exhibit therapeutic activity against leishmania, such as 
Kalanchoe pinnata, Plumbago scandens, Physalis angulata, Piper aduncum, Tabemaemontana australis, 
and Phyllanthus amarus [95]. 
Alkaloids, as secondary metabolites, are particularly relevant in plants as a source of 
protection against various microorganisms and herbivores. These compounds are equally 
essential for man when applied to kill parasites. A countless number of alkaloids are described 
with noteworthy leishmanicidal activity, but without clinical results due to lack of clinical trials. 
The chemical structure of alkaloids with evidenced leishmanicidal activity is related to quinoline, 
indole, isoquinoline, naphthylisoquinoline, bisbenzylisoquinoline, estrogens, 
benzoquinolizidine, diterpenes, pyrrolidinium, acridone, β-carboline and marine sponge-derived 
terpenoids [96]. Table 2 lists the compounds with potential therapeutic value in the treatment of 
LM. 
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Table 2. Description of the compounds with potential therapeutic value in the treatment of 
Leishmaniasis (LM) [97–104]. 
Compound Natural Sources Targeted Parasite 
Classes of 
Compounds 
Renieramycin A Neopetrosia L. amazonensis Alkaloids 
Cyclic peroxide Plakortis aff angulospiculatus L. mexicana - 
Valinomycin Streptomycers spp. L. major promastigotes - 
Agelasine D Agelas nakamurai L. infantum - 
Diphyllin Haplophyllum bucharicum 
L. infantum intracelular 
amastigotes and 
promastigotes 
Lignans 
10-deacetylbaccatin III Taxus baccata L. donovani amastigotes Taxoids 
Linalool Croton cajuçara 
L. amazonensis 
promastigotes and 
intracellular amastigotes 
Terpenes (mono) 
7-hydroxy-12-methoxy-20-nor-
abieta-1,5(10),7,9,12-pentaen-
6,14-dione Salvia cilicica 
L. donovani and L. major 
intracellular amastigotes 
Terpenes 
Abieta-8,12-dien-11,14-dione 
- Lophanthera lactescens L. amazonensis amastigotes Triterpenes (nor-) 
Isoiguesterin 
Salacia madagascariensis 
L. donovani and L. 
mexicana 
Terpenes 
20-epi-isoiguesterinol 
8-epixanthatin 1_,5_-epoxide Xanthium brasilicum Vell L. donovani 
Terpenes (lactone 
sesqui-) 
Elephantopin 
Elephantopus mollis 
L. major extracellular 
promastigotes 
Terpenes (lactone 
sesqui-) 2-deethoxy-2_-
methoxyphantomolin 
Psilostachyin Ambrosia tenuifolia 
Leishmania spp. 
promastigotes 
Terpenes (lactone 
sesqui-) 
Simalikalactone D Simaba orinocensis L. donovani promastigotes 
Terpenoids 
(Decanortri-) 
Acetylvismione D Psorospermum glaberrimum L. donovani Anthranoids 
Dicentrinone Duguetia furfuracea 
L. braziliensis 
promastigotes Alkaloids 
Jatrogrossidione Jatropha grossidentata 
Leishmania spp.  
amastigotes 
Terpenes (di-) 
Jatrophone Jatropha isabellii L. amazonensis Terpenes (di-) 
Oleanolic acid 
Salvia cilicica 
L. donovani and L. major 
promastigotes and 
amastigotes 
Terpenes (tri-) 
Ursolic acid 
Luteolin 
- Leishmania spp. Flavonoids 
Quercetin 
6,7-dihydroneridienone Pentalinon andrieuxii L. mexicana Sterols 
Licochalcone A Glycyrrhiza spp 
L. major and L. donovani 
promastigotes and 
amastigotes 
Chalcone 
(oxygenated) 
 
20,60-dihydroxy-40-methoxy-
chalcone 
Piper aduncum 
 
Leishmania spp. 
Chalcones 
derivatives 
- - 
Leishmania spp. 
promastigotes 
Aurones 
- C. brasiliense L. amazonensis Coumarins 
Casuarinin 
Punica granatum, Casuarina, and Stachyurus 
species 
L. donovani Tannins 
Amarogentin Swertia chirata L. donovani 
Iridoids (glycoside 
seco-) 
Plumbagin 
Pera benensis 
L. donovani promastigotes 
and intracellular 
amastigotes and L. 
amazonensis amastigotes 
and L. braziliensis and L. 
venezuelensis 
Naphthoquinones 
8,80-biplumbagin 
Burmanin A 
Diospyros burmanica L. major Naphthoquinones Burmanin B 
Burmanin C 
Pendulone 
Miconia lepidota L. donovani 
 
Quinones 
Primin 
Chimanine B 
Galipea longiflora L. amazonensis 
Alkaloids 
(quinoline 
derivatives) Chimanine D 
Cephaeline Psychotria klugii L. donovani Alkaloids 
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Isocephaeline 
Klugine 
Harmine Peganum harmala Leishmania spp. Alkaloids 
Maesabalides III 
Maesa balansae L. infantum intracellular 
amastigotes 
Saponins 
Maesabalides IV 
Racemoside A Asparagus racemosus L. donovani amastigotes Saponins 
α- and β-Hederine 
Hedera helix 
L. infantum promastigotes 
and intracellular 
amastigotes 
Saponins 
Hederacholchiside A1 
α-bisabolol Matricaria recutita, Matricaria chamomilla and Vanillosmopsis arborea L. amazonensis Sesquiterpenes 
Undeca-2E,4E-dien-8,10-diynoic 
acid isopentylamide 
Anacyclus pyrethrum L. donavani Alkamides 
Tetradeca-2E,4E,12Z-trien-8,10-
diynoic acid isobutylamide 
Deca-2E,4E,9-trienoic acid 
isobutylamide 
5-methyl-2,2′:5′,2″-terthiophene 
Porophyllum ruderale 
L. amazonensis 
promastigotes and 
amastigotes 
Thiophene 
derivatives 5′-methyl-[5-(4-acetoxy-1-
butynyl)]-2,2′-bithiophene 
Caffeic acid 
P. carolinensis, P. rosea and P. odorata 
L. amazonensis 
promastigotes and 
intracellular amastigotes 
- 
Chlorogenic acid 
Ferulic acid 
Quercetin 
Rosmarinic acid 
- 
Artemisia absinthium L. 
Artemisia dracunculus L. 
Artemisia seiberi L. 
Artemisia ludoviciana Nutt 
Artemisia abyssinica Sch.Bip 
L. amazonensis 
L. aethiopica and L. 
donovani 
- 
- 
Aphelandra scabra (leaves), Byrsonima 
bucidaefolia (bark), Byrsonima crassifolia 
(bark), Clusia flava (leaves), Cupania dentata 
(bark), Diphysa carthagenensis (leaves), 
Dorstenia contrajerva (complete plant), 
Milleria quinqueflora (root), Tridax 
procumbens (complete plant), and Vitex 
gaumeri (bark) 
L. mexicana promastigotes 
 
- 
- 
Urechites andrieuxii; Colubrina greggii, 
Dorstenia contrajerva, and Tridax procumbens L. aethiopica promastigotes - 
3(S)-16,17-didehydrofalcarinol or 
oxylipin 
T. procumbens 
L. mexicana promastigotes 
and intracellular 
amastigotes 
 
- 
Cholest-5,20,24-trien-3𝛽-ol 
U. andrieuxii 
L. braziliensis and L. 
amazonensis and L. 
donovani and L. mexicana 
promastigotes and 
amastigotes 
- 
6,7-dihydroneridienone 
Methylcholest-4-24(28)-dien-3-
one, cholest-4-en-3-one 
Pentalinosterol 
Neridienone 
Diospyrin Euclea natalensis L. donovani promastigotes - 
Racemoside A Asparagus racemosus L. donovani promastigotes 
and amastigotes 
Saponins 
Amarogentin Swertia chirata L. donovani 
Iridoids 
(glucoseco-) 
Mesabalide III 
Maesa balansae 
L. infantum intracellular 
amastigotes 
Saponins 
Mesabalide VI 
Crocaudatol 
Croton caudatus 
L. donovani promastigotes 
and intracellular 
amastigotes 
 
Terpenes 
Crotocaudin 
Crotoncaudatin 
Isocrotocaudin 
Glycyrrhizic acid 
Glycyrrhiza glabra 
A. indica 
L. donovani intracellular 
amastigotes 
- 
2-phenylquinoline Angostura longiflora (Krause) Kallunki L. braziliensis Alkaloids 
6𝛼,7𝛼,15𝛽,16𝛽,24-pentacetoxy-
22𝛼-carbometoxy-21𝛽,22𝛽-epoxy-
18𝛽-hydroxy-27,30-bisnor-3,4-
secofriedela-1,20(29)-dien-3,4 R-
olide 
Lophanthera lactescens Ducke 
Leishmania spp. 
intracellular amastigotes 
Triterpenes (nor-) 
Piperine Piper nigrum Alkaloids 
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Phenylamide 
L. amazonensis 
promastigotes and 
amastigotes 
β-pinene Artemisia campestris L. infantum promastigotes - 
Camphor Artemisia herba-alba L. infantum promastigotes - 
Camphor 
Artemisia annua 
L. donovani promastigotes 
and 
amastigotes 
 
- β-caryophyllene 
Buchtienin 
Kopsia griffithii L. donovani promastigotes Alkaloids (indole) Harmane 
Pleiocarpin 
Ramiflorines A and B Ampelocera edentula 
L. braziliensis and L. 
amazonensis, and L. 
donovani promastigotes 
Alkaloids 
2𝛼,3𝛽-dihydroxyursan-12-in-28-
oic acid 
Pourouma guianensis 
L. amazonensis 
promastigotes and 
intracellular amastigotes 
- 
2𝛼,3𝛽-dihydroxyolean-12-in-oic 
acid 
Oleanolic acid 
Ursolic acid 
In recent decades, efforts have been made worldwide with the aim to find therapeutic 
solutions for CD with less adverse events for patients under treatment. The success encountered 
in this attempt depends on several factors: (i) the phase of the disease in which patients start the 
treatment (usually, it occurs predominantly at the later stage due to the asymptomatic acute 
phase of CD), (ii) the diversity of resistance profiles of parasites, (iii) the difficulty in the 
employment of the correct type of drug for individual patients (broad or narrow spectrum drugs) 
and, most importantly (iv) on the limited funding attributed to research groups devoted to the 
discovery of new targets and drugs. 
Current data about the parasites, their life cycle and the known critical cell biomolecules 
required for the development of these plagues, drive researchers to look into the nature of 
potential therapeutic molecules as in loco microbiota of some flora and fauna develop 
mechanisms against these aggressors. Table 3 lists the compounds with potential therapeutic 
value in the treatment of CD. 
Table 3. Description of the compounds with potential therapeutic value in the treatment of 
Chagas’s disease (CD) [101,105–109]. 
Compound Natural Sources Targeted Parasite Classes of Compounds 
Helenalin 
Arnica spp. and Inula spp. 
T. brucei rhodesiense 
trypomastigotes Terpenes (sesquiterpene lactones) Mexicanin I 
Parthenolide Saussurea costus T. brucei rhodesiense Terpenes (sesquiterpene lactones) 
Primin Miconia lepidota T. brucei rhodesiense Quinones 
7,8-dihydroxyflavone 
- T. brucei rhodesiense 
Flavones 
Quercetagetin Flavonols 
Demethylpraecansone B 
Tephrosia aequilata T. brucei rhodesiense Chalcones 
Praecansone B 
Justicidin B 
- T. brucei rhodesiense Lignans (arylnaphthalide) 
Piscatorin 
Cissampeloflavone Cissampelos pareira T. brucei rhodesiense Chalcones (flavone-chalcone dimer) 
Lepadins D Didemnum spp. T. brucei rhodesiense 
trypomastigotes 
Quinolines (decahydroquinoline) 
Fascaplysin Hyrtios erecta T. brucei rhodesiense Alkaloids (quaternary indole) 
Ascididemin 
- T. brucei rhodesiense Alkaloids (pyridoacridone) 
2-bromoascididemin 
Manadoperoxide B 
Plakortis cfr. Lita T. brucei rhodesiense Peroxide derivatives Manadoperoxide I 
Manadoperoxide K 
Pandaroside G methyl ester Pandaros acanthifolium T. brucei rhodesiense Steroids (saponins) 
Dibromopalau’amine Axinella verrucosa T. brucei rhodesiense Oroidins (dimer) 
Brassicasterol Chondrosia reniformis and 
Tethya rubra and 
Tethya ignis and 
Mycale angulosa and 
Dysidea avara 
T. cruzi 
epimastigotes 
 
Steroids (sterols) 
β-sitosterol 
Stigmasterol 
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 Rhodnius prolixus T. rangelii Lectins 
Quercetin Guazuma ulmifolia T. cruzi Flavones 
Naringenin 
- 
T. cruzi 
trypomastigotes and 
amastigotes 
Flavanones 
Sakuranetin 
Borneol 
Croton pedicellatus and 
Croton leptostachyus 
 
T. cruzi - 
γ-terpinene 
p-cymene 
trans-caryophyllene 
Germacrene D 
Artemisinin 
A. absinthium and A. annua T. cruzi - 
α-thujone 
β-thujone 
sabinene 
β-pinene 
Myrcene 
trans-sabinyl acetate 
1,8-cineole 
Linalool 
cis-epoxyocimene 
Artemisiaketone 
Camphor 
Bornyl acetate 
Myrtenol 
Chrysanthenyl acetate 
hydrocarbon monoterpenes 
Sesquiterpene lactones 
Dihydrochamazulene 
trans-caryophyllene 
4-hydroxy-3-
tetraprenylphenylacetic acid 
Spongia spp. and Ircinia spp T.b. rhodesiense 
Terpenes (furanoterpenes and 
meroterpenes and 
di- and tri-terpenes) 
11β-acetoxyspongi-12-en-16-
one 
Demethylfurospongin-4 
24-ethyl-cholest-5α-7-en-3-β-
ol 
Agelas oroides T.b. rhodesiense Steroids (sterol) 
Pandaroside G Pandaros acanthifolium 
T.b. brucei and T. 
cruzi 
Steroids (saponins) 
Acanthifolioside E 
- 
T.b. rhodesiense 
and T. cruzi 
Steroids (saponins) and Terpenes 
(acanthifolisides) Acanthifolioside F methyl 
ester 
Plakortide P Plakortis angulospiculatus T. cruzi Polyketide endoperoxides 
11,12-didehydro-13-oxo-
plakortide Q 
Plakortis sp T.b. brucei - 
10-carboxy-11,12,13, 14-
tetranor-plakortide Q 
Manadoperoxides B 
Plakortis cfr. lita T.b. rhodesiense - Manadoperoxide G 
Peroxyplakoric ester B3 
Tetronic acid-containing 
tetromycin B 
Axinella polypoides T.b. brucei - 
Tetromycins 1 
Tetromycins 3 
- Chaetomium sp. T.b. rhodesiense 
Xanthone (heterocyclic-substituted 
analogues) 
Tryptophol Ircinia spinulosa T.b. rhodesiense Alkaloids (indole-) 
3-formylindole 
Anthiphates sp T. cruzi Alkaloids (indole-) 3-hydroxyacetylindole 
N-acetyl-β-oxotryptamine 
Opacalines A 
Pseudodistoma opacum T.b. rhodesiense 
Alkaloids (alkylguanidine-
substituted β-carboline-) Opacalines B 
Opacalines C 
Amino-1-(aminoimidazoyl)-
prop-1-ene 
Agelas oroides 
T.b. rhodesiense and T. 
cruzi 
Bromopyrrole derivatives 
Oroidin trifluoroacetate salt Agelas oroides T.b. rhodesiense Bromopyrrole derivatives 
Longamide B Agelas dispar T.b. rhodesiense 
Alkaloids 
 
Longamide A Agelas longissima T.b. rhodesiense 
Alkaloids 
 
Oroidin dimer 
dibromopalau’amine 
Axinella verrucosa T.b. rhodesiense 
Alkaloids 
 
Pathogens 2019, 8, 119 14 of 28 
Sceptrin Agelas sceptrum T.b. rhodesiense 
Alkaloids 
 
Agelasine D Agelas nakamurai 
T.b. brucei and T. 
cruzi 
Terpenes (bicyclic diterpenoid 
purine) 
Convolutamines I 
Amathia tortusa T.b. brucei Alkaloids (brominated β-phenyl 
ethylamine-based) Convolutamines J 
Iotrochotamide A 
Iotrochota sp. T.b. brucei 
Amino acids (cinnamoyl amino 
acids) Iotrochotamide B 
Lepadins D 
Didemnum sp. 
T.b. rhodesiense 
and T. cruzi 
Alkaloids (decahydroquinoline) Lepadins E 
Lepadins F 
Viscosamine Haliclona viscosa T.b. brucei Alkaloids (3-alkylpyridinium) 
Fascaplysin Hyrtios cf. erecta T.b. rhodesiense Alkaloids (pentacyclic bis-indole) 
Ascididemnin 
Polysyncraton echinatum T.b. brucei Alkaloids (pyridoacridines) 
12-deoxyascididemnin 
- Aspergillus fumigatus T.b. brucei 
Alkaloids (dimethylthio, spiro-
pentacyclic and fused penta- and 
hexacyclic diketopiperazines) 
Chaetocin 
Nectria inventa T. cruzi 
Alkaloids (dimethylthio and two 
disulfide diketopiperazines) Verticilin B 
Venturamides A 
Oscillatoria sp T. cruzi Cyclic peptides 
Venturamides B 
Aerucyclamides B 
Microrcystis aeruginosa T.b. rhodesiense Alkaloids 
Aerucyclamides C 
Almiramides B 
Lyngbya majuscula T.b. brucei Alkaloids 
Almiramides C 
- 
Liriodendron tulipifera and 
Lychnophora diamantinana and 
Viguiera robusta and Eremanthus 
goyazensis and Helianthus tuberosus 
T.b. rhodesiense Sesquiterpenes (lactones) 
8-epixanthatin 1,5-epoxide  T.b. rhodesiense Sesquiterpenes (lactones) 
Sinefungin 
Streptomyces grizeolus and S. 
incarnates 
T. brucei and T. 
congolense and T. 
vivax 
- 
Aculeatin D Amomum aculeatum 
T. brucei rhodesiense 
trypomastigotes Aculeatins 
Ferruginol 
Craniolaria annua 
T. cruzi 
trypomastigotes and 
epimastigotes 
Abietanes (phenolic) 
Montbretol 
α-solamargine Solanum lycocarpum and Solanum 
palinacanthum T. cruzi Alkaloids (glycoalkaloids) α-solasonine 
5. New drug delivery systems 
A range of new drug delivery systems (DDS), such as liposomes, microemulsions, and 
micro/nanoparticles, proved to be very useful for the pharmaceutical industry. New liposome-
based drug delivery systems are the most commonly used DDS due to their high 
biocompatibility, manufacture simplicity and chemical variability. They are biodegradable, 
biocompatible, non-immunogenic and highly versatile for research, analytical and therapeutic 
applications [110]. 
DDS are an additional alternative to the design of new drugs and combined therapy for VL. 
Such systems can preserve the medicine against the first pass metabolism upon oral 
administration and are also suitable for administration by other routes. DDS can overcome the 
limitations of reduced water solubility, in the same way as they allow the simultaneous transport 
of several drugs, thus facilitating the application of combination therapy [111]. 
The limitation of conventional therapy may be attributed to difficult and inadequate 
diagnosis, cases of drug resistance, inaccurate dosage, difficulties in adequately monitoring the 
dose, frequency of administration, poor patient compliance, lack of physical procedures to 
support the treatment, inadequate immune response of patients to therapy. Some other 
biopharmaceutical aspects govern the design of DDS including drug permeability through cell 
membranes, the mechanism of cell uptake (especially in the case of intracellular parasitic 
infections), stability, activity and kinetics in the target cell environment [112,113].  
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Liposomes and nanoparticles are especially viable against VL (depending on the drug they 
carry), because they are more easily captured by the mononuclear phagocytic system, which 
becomes an additional advantage in the treatment of this pathology. In fact, intraperitoneal (IP) 
and intravenous (IV) administration of liposomes was proven to be an excellent approach as it 
increased the accumulation of the drug-loaded liposomes in tissues with high concentration of 
macrophages, such as the spleen and liver—organs where Leishmania parasites are also present 
in vast quantities [114,115]. 
Liposomes are vesicles consisting of one or more phospholipid bilayers surrounding an 
aqueous core [116]. Some studies demonstrated that liposomes-encapsulated antimony had a 700-
fold therapeutic effect against canine LM when compared to the non-encapsulated form [117]. 
Another example of a drug developed in this context was liposomal AmB (AmBisome®), which 
was shown to be 350 to 750-fold more effective than non-encapsulated meglumine antimonate 
and AmB. The latter formulation decreased the toxic effects at a cellular level with improved 
stability and activity against VL [118]. Currently, this is the only DDS-based product authorized 
for LM therapy. The example of liposomal AmB clearly shows that the design of DDS can 
substantially improve the performance of loaded drugs.  
Niosomes are vesicles consisting of non-ionic surfactants and cholesterol with similar 
characteristics as liposomes. In order to be cost-effective, safe and allow optimizing the 
therapeutic effect against LM, the surfactants require a thorough selection process [119]. AmB, in 
combination with selenium, has been recently formulated in niosomes [120]. The combined 
noisome therapy exhibited higher inhibitory effect on the promastigote and amastigote forms of 
Leishmania tropica L. than the non-loaded form. The loaded form significantly decreased the 
levels of interleukin-10, while the levels of IL-12 and metacasoase (as Th-1 activator) significantly 
increased. 
Solid lipid nanoparticles (SLN) consist of nanoscaled DDS with the matrix composed of solid 
lipids at room and body temperatures [121,122]. These systems are considered highly safe and 
simple to manufacture in a substantial extent. They also allow controlled release of drugs and 
immediate removal by the liver and spleen [123]. Although the trials still do not allow draw 
conclusions, SLN may be proposed to promote leishmanicidal and antimalarial effects [124]. 
Enhanced drug absorption at the hepatic level has been reported, as well as the increase in the 
leishmanicidal therapeutic effect using mannose-coated AmB lipid nanospheres [125]. 
Other patented AmB lipid-based DDS for therapeutic use are the colloidal dispersions of 
AmB (Amphocil®) and the lipid complexes of AmB (Amphotec®). These DDS also decreased the 
toxic effects and increased the therapeutic index of loaded drugs [126]. AmBisome® is applied for 
the treatment of parenteral VL, already having generics in the market [127].  
Otheres class of DDS are the polymeric nanoparticles, which can be further divided into 
nanospheres, when the matrix is composed of chains of continuous interconnected polymers, and 
nanocapsules—resulting from the surrounding of oil or water nanoparticles by a thin polymer 
coating. Both types of nanoparticles allow optimizing the release of the drug [128].  
Primaquine-loaded nanoparticles were tested, with a 21-fold higher response in terms of 
drug release and with fewer side effects [129]. Similar results were observed with the use of 
nanoparticles containing AmB [130]. Pentamidine nanoparticles were also evaluated, and the 
response was 25-fold higher in terms of drug release and with less side effects [131]. 
As previously mentioned, with the exception of miltefosine and sitamaquine, leishmanicidal 
drugs have a very low oral bioavailability. This aspect is the result of a highly frequent enzymatic 
decomposition, reduced membrane permeation at the level of the intestine and, more relevant, 
the reduced solubility in water. To overcome these limitations, some alternatives may be adopted, 
such as oral DDS, aimed at increasing drug solubility, improving its half-life and absorption 
profile [132]. 
5.1. Targeting the values of apparent solubility 
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DDS increase the contact area of the drug with the absorption tissue and facilitate 
decomposition in the GI tract in case of oral administration. Polymeric nanoparticles and 
nanosuspensions are some examples [133]. A study conducted with AmB, formulated in 
nanocapsules containing poly(lactic-co-glycolic acid) (PLGA) nanocapsules, found it to be 8-fold 
superior to Fungizone®, both in oral bioavailability as well as in antifungal activity [134]. 
Nanosuspensions are composed of the drug crystals surrounded by a surfactant layer, generally 
in the form of an aqueous dispersion. Some antiparasitic agents were analyzed in 
nanosuspensions and successfully evaluated by in vitro and in vivo assays against Leishmania 
[135]. Particularly noteworthy is the nanosuspension of AmB having a particle size of 
approximately 530 nm, obtained by high pressure homogenization (HPH) with a set of 
surfactants: pluronic F68, Tween 80 and sodium cholate. This formulation was more effective 
against VL after oral administration in the rat, than AmBisome®, Fungizone® and micronized 
AmB administered under the same conditions, which showed no activity [136]. 
5.1.1. Cyclodextrin complexes 
Another way of increasing drug solubility to assist oral absorption is using cyclodextrins. 
Cyclodextrins are hydrophilic cyclic oligosaccharides which possess a hydrophilic extrinsic space 
and a central lipophilic concavity employed as promoters of drug absorption upon delivery. 
Generally, the hydrophobic drugs are encapsulated in the central opening, increasing the drug 
water solubility [137]. Through a sequence of tests, it has been proved that meglumine 
antimoniate complexed with cyclodextrin yielded an improved oral bioavailability [138]. 
5.1.2. Modification in the absorption behavior 
Lipid-based DDS (e.g., micro/nanoemulsions, mixed micelles and lipid-based nanoparticles 
[139–141]) have a high ability to improve drug bioavailability. Using lipids as additives, they 
improve drug absorption in the gut and may be also metabolized by the gastrointestinal (GI) 
enzymes.  
An emulsion is a dispersion of small droplets of a liquid in a second liquid in which the first 
is not miscible and usually requires one or more surfactants to balance the interface. For 
nanoemulsions, the droplets are within the nanometer range [142]. The production of an AmB-
loaded oil-in-water (O/W) microemulsion showed ability to increase drug dissolution by 1000-
fold with a reduction in toxic effects on cells [143]. Also, another test performed with a self-
emulsifying formulation of AmB with mono- and diglycerides plus vitamin E (stabilizer) proved 
to be stable in the intestinal fluid with the AmB concentration remaining constant for 6 hours and 
with improved oral bioavailability [144]. Mixed micelles with amphiphilic compounds are able 
to reproduce the physiological systems where the lipids from the food are transformed into mixed 
micelles constituted by bile salts [145]. AmB-loaded micelles composed of phospholipids and bile 
acids improved the absorption of the drug in a prototype of intestinal loop perfusion in rats, 
although not tested in the healthy animal [146]. Lipid-based nanoparticles have benefits 
compared to other oral DDS, since they possess good physical stability and simplicity to obtain 
hydrophobic drugs. Besides SLN, cubosomes and nanocochleats have also been described [147]. 
Their effects were studied against LM, and an AmB-based formulation was developed 
exclusively for oral administration. The study reported an increased bioavailability response, as 
well as increased half-life through controlled drug release [148]. 
Cubosomes are crystalline lipid structures with cubic symmetry formed by amphiphilic 
molecules which contain two alternating nonhomogeneous aqueous phases delimited by lipid 
bilayers. They have a great ability to encapsulate hydrophilic active substances, protecting them 
against the external environment. Consequently, they are suitable for oral administration [149]. 
A study was carried out with cubosomes containing AmB, but there was no biological response 
[150]. Nanocochleats are cigar-shaped nanostructures consisting of negatively charged lipid 
bilayers, attached to a divalent cation, usually calcium. The benefits of this type of DDS are 
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essentially the safety they provide to the drug against the GI medium, defense against oxidation 
and preservation of the morphology after lyophilization, which allows its storage for extended 
periods at room temperature [151]. AmB-loaded nanocochleats showed improved oral 
absorption and antifungal activity relative to free AmB [152]. 
5.1.3. Increase in resistance time 
Another alternative that aims to promote the oral bioavailability of drugs is the increase in 
the drug residence time at the absorption site. When binding the intestinal wall, the DDS increase 
the local concentration gradient of the drug at the absorption site, by prolonged contact of the 
DDS with the mucus, increasing the portion of drug capable of being absorbed. Moreover, the 
DDS may include additives to promote diffusion through the mucosal epithelium and thus 
favoring drug permeation [153].  
Chitosan is an interesting polysaccharide, combining bio-adhesion with absorption-
enhancing characteristics. Chitosan is a natural polysaccharide composed of glucosamine and N-
acetylglucosamine which is obtained from chitin of crustaceans. This compound may further 
function as an absorption promoter through the intestinal epithelium, due to its capacity to 
strengthen the diffusion of mucoadhesive systems. Recently, a preparation of chitosan 
nanoparticles demonstrated a reduction in toxic effects via IV administration and good 
leishmanicidal activity in a rat model [154]. 
The main challenge of CD pharmacotherapy is reaching the overall disseminated 
intracellular parasites. Intracellular bacterial infections caused by protozoa present physical 
barriers that hinder the arrival of significant portions of the drug to the target site. However, BNZ 
and NF exhibit a high volume of distribution (Vd) and with a poor access to intracellular targets 
leading to high plasma concentrations and toxic effects. The ability to alter the surface of target 
cells and tissues as well as phagocytosis offers DDS the ability to circumvent these natural 
barriers and transport the drugs in an extraordinarily small volume, reducing their concentration 
in circulating fluids and non-target tissues [155,156]. Therefore, the efficacy of liposomes against 
trypanosomiasis or CD has been investigated to a much lower extent than LM. This state possibly 
results from the widespread positioning of the parasites in cells of the mononuclear phagocytic 
system (MPS) making them difficult to reach with the use of liposomes, which are defined by 
agglomerating in MPS after IV injection [157]. 
Nakae et al., in two studies, evaluated the efficacy of stearylamine-liposomes with positive 
charge (drug-free) against Trypanossoma cruzi. More interestingly, positively charged liposomes 
with phosphatidylcholine and stearylamine demonstrated the ability to destroy Trypanossoma 
cruzi in a brief time (30 minutes), at a moderately reduced lipid dose (10 µM) and without toxicity 
to erythrocytes. In turn, phosphatidylcholine and stearylamine tested alone did not reveal any 
activity against parasites, reinforcing the idea that the association of both in a liposome is of 
extreme relevance for antiparasitic activity [158,159]. 
Another study, conducted by Morilla et al., with liposomes encapsulated with BNZ, 
concluded that although their concentration in liver and blood increased, the efficacy of this 
formulation in the treatment of CD was not feasible, since liposomes were not capable to make 
BNZ reach the cytoplasm, where the parasite is usually located [160]. Morilla et al., in another 
study, evaluated the usefulness of pH-sensitive liposomes incorporated with etanidazole (ETZ) 
to promote the arrival of this type of liposome into the cytoplasm. This attempt, unlike ETZ alone 
which did not show any activity, resulted in approximately 72% of parasites dead and 
parasitemia reduction. Nonetheless, this association did not eliminate the parasite, but 
contributed to the advancement of upcoming studies with liposomes pH-sensitive [161]. 
Yardley et al. related the activity of AmB in vitro and in vivo, namely in the products 
AmBisome®, Amphocil®, Abelect®, for the treatment of CD. Although Amphocil® proved to be 
more efficient in vitro, Ambisome® demonstrated superior activity in reducing parasitemia in 
vivo than the other formulations [162]. 
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Gonzalez-Martin et al. pointed out the utility of NF-loaded polyethylcyanoacrylate 
nanospheres targeted against trypomastigotes and intracellular amastigotes with IC50 results 
demonstrating a 21-fold lower proliferation in comparison with non-encapsulated drug 
treatments [163]. The same authors also demonstrated the in vitro activity of allopurinol-loaded 
polyethylcyanoacrylate nanospheres against Trypanossoma cruzi epimastigotes, with a response 
twice as effective in comparison with the free drug. However, to be validated, the studies require 
in vivo confirmation of the nanospheres efficacy [164]. Molina et al. performed an experiment 
with DO870 nanoparticles (PEG and lactic acid) injected intravenously in a mouse model infected 
with Trypanossoma cruzi [165]. The formulation led to the cure of trypanosomiasis with a dose-
dependent activity. Regardless of the few advances achieved through these studies, they are 
expected to contribute to original approaches as they are still very inconclusive and require 
further research. 
In the last decade, the progress of nanoscience has similarly been applied to drugs of natural 
origin, producing promising and useful tools in the treatment of several pathologies, including 
LM. Nanometric-scale formulations prepared with products derived from medicinal plants and 
their leishmanicidal activity are reported below, with liposomes, niosomes, and nanoparticles as 
the main addressed systems. Saponins (liposomes) and alkaloids (nanoparticles) are the essential 
plant components used in these frameworks. A considerable effectiveness of flavonoids against 
Trypanossoma and Leishmania species has been described by means of an assay using quercetin. 
Following studies tested quercetin formulated in niosomes, liposomes and microspheres, with 
overall experimental hypothesis demonstrating reduced parasitemia relatively to the free drug, 
from which can be deducted that encapsulated quercetin is more effective in containing LM 
[166,167]. 
The loading of terpenoids in micro/nanoparticles also exhibited therapeutic activity. Yet, 
effective drugs against LM are still a demand, while most products are characterized by their low 
solubility compromising the drug bioavailability. Nanoparticles loaded with andrografolide, a 
diterpenoid extracted from the Andrographis paniculata, displayed strong leishmanicidal activity 
[168]. It was also proved that particle size is a relevant factor for drug transport efficiency. In fact, 
nanoparticles with smaller than 200 nm have been linked to increased phagocytosis by 
macrophages infected with Leishmania [169,170]. 
Another study with multiparticle systems, including niosomes, microspheres, liposomes 
and nanoparticles, improved leishmanicidal activity with the use of Bacosaponine-C (extracted 
from Bacopa monnieri), by reducing the parasitic load on the spleen of hamsters compared to 
animals tested with free drug. With the same compound amount, the best activity, in diminishing 
order, was observed for: nanocapsules > niosomes > liposomes > microspheres [171]. Despite the 
promising results, the use of saponins is restricted as a consequence of their high toxicity. 
Another compound with a visible effect against LM is amarogentine (obtained from 
Swertiachirata). The liposomal and niosomal preparations of this molecule decreased the parasite 
incidence in the spleen by 69 and 90%, respectively, while the free drug in the same amount 
obtained an outcome of 39% [172]. In turn, the piperine alkaloid (extracted from the Piper nigrum), 
had a strong effect against both VL and TL. The loading of this substance in liposomes reduced 
the parasitemia by approximately 70%, whereas, in its free form (in addition to being less 
effective), it also demonstrated greater toxicity with the top results obtained with piperine 
nanospheres [173]. Harmine (isolated from Syrian Arruda) manifested leishmanicidal activity in 
vitro and, when incorporated into liposomes, niosomes, or nanoparticles, this alkaloid was able 
to reduce parasitemia in the spleen of infected animals. However, the harmine action mechanism 
against Leishmania is poorly elucidated, thus requiring further study [174]. 
5.1.4. Programmed cell death 
Programmed cell death (PCD) is described as a strictly controlled event allowing organisms 
to reject cells, thereby preventing inflammation usually occurring in injured surrounding cells. 
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This process was described for the first time in the 1970s and, since then, it is being used to 
describe cancer and degenerative disorders. PCD allows a distinct type of cell death depending 
on the organism—mostly eukaryotic cells. In recent years, PCD has also been described in 
prokaryotes [175]. 
Leishmania and Trypanosoma cruzi are unicellular protozoa, being the etiological cause of LM 
and CD, respectively. Their life cycle development requires several stages, which entail various 
hosts until they infect humans and proliferate. Current literature highlights the importance of 
PCD in the differentiation of infectious and non-infectious forms of these parasites. The infectious 
forms do not divide while the non-infectious forms have an undefined track. Some phenotypical 
features of these protozoa are similar to eukaryotes such as the loss of the depolarization of 
mitochondria membrane, exposure of phosphatidylserine to the outer aspect of the cell 
membrane, breakage of DNA structure, cytochrome C release from the mitochondria and 
enhanced proteolytic activity. A similar expression of molecules in the transduction signals of 
PCD in eukaryotes was also demonstrated for these parasites. Both in vitro (using distinct harsh 
conditions as AmB or H2O2) and in vivo (using L. donovani amastigotes extracted from 
macrophages of patients treated for LM) assays detected signals of evidence of PCD [176].  
Despite the prediction of similar mechanisms on PCD, researchers now have indication that 
this occurrence of PCD in prokaryotes is a distinct event from apoptotic conditions in mammalian 
organisms.  
The reason behind the presence of such forms of PCD is still unclear but is probably linked 
to the required cell machineries in these organisms to evolve and resist to host defenses. 
Regarding Leishmania, the transmittable form of the parasite is the metacyclic form, which 
develops from procyclic promastigotes inside the vector. The first form of the parasite is capable 
of infecting the hosts, evolving to amastigotes and initiating an infectious process. The process of 
differentiation does not occur in every single cell and, because of that, PCD may possibly be a 
process to select only the viable cells to perpetuate the species. This is achievable as the non-
infectious parasites would be eliminated and, so, only infectious forms would use the nutrients 
required to survive and proliferate. After infecting the organism, the parasite amastigote form 
reproduces slowly over the years and releases the infectious form to the bloodstream but without 
triggering an inflammatory process. To achieve such a status, PCD may have a prominent role 
here by allowing phagocytes, namely macrophages, to be infected by T-lymphocytes undergoing 
apoptosis, rendering a refractory reply of macrophages to cytokines and yielding parasite 
survival. As both T. cruzi and L. donovani can undergo PCD, the halted immune response can be 
achieved, and parasite replication allowed. This fact is of topmost importance as a criterion for 
the development of new therapeutic strategies regarding the inhibition of key molecules in this 
event, which might contribute to future development in LM and CD therapeutics [177]. 
6. Conclusions 
Chemotherapy is still the strategy of choice to eradicate NDs. This approach assists not only 
as a means of intervention and reestablishment of people infected by such pathologies, but also 
for health protection and the set-up of surveillance services. Pharmacovigilance, although still 
largely neglected, is extremely important and should be considered by professionals and health 
systems, especially in these scenarios, where knowledge about patients and transmission courses 
is relevant. The drugs used in ND therapy are old-fashioned in their design, possess side effects 
and present a high resistance profile, resulting in the need for the development of new drugs that 
present bioequivalence in vivo. Other important measures, which should receive further 
attention from governments, include reinforcements of the inhabitant’s education in these 
endemic areas, improving rudimentary hygiene, sanitation and monetary supplies. One of the 
limitations of pharmacological treatment is the failure to adopt some of these measures, leading 
to the spread of these infections. The only two drugs currently used in the treatment of CD are 
strictly active against the acute phase of the disease but not against the chronic. Furthermore, the 
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adverse reactions arising from the administration of such molecules are harmful and are 
responsible for the poor patient compliance to therapeutics. Concerning LM, despite the progress 
already made in the knowledge of the parasite, the therapy still fails due to the enormous 
diversity of existing species with diverse characteristics. In this way, the lack of control of these 
pathologies may lead to the exacerbation of other illnesses, as is the case of HIV. In this sense, 
there is a vital need to develop new therapeutic systems that aim to overcome these limitations 
and improve the transport of the drugs to the target site, assuring an increase in therapeutic 
efficacy. One of the main objectives of new DDS is to design formulations that can be 
administered orally. DDS are extremely useful for poorly soluble drugs in water, as in the case of 
amphotericin B because they are formulated as dispersions, facilitating drug dissolution. These 
systems also have high amount of lipids, which contribute to drug absorption and longer 
residence time in the GI tract. Another interesting strategy is pharmaceutical research in the field 
of medicinal plant-derived compounds. The combination of phytochemistry with 
nanotechnology aims to create new possibilities on the screening of new antiparasitic drugs, since 
these preparations can enhance the activity of natural compounds. This is a field enriched in 
possibilities. However, most of the studies are still limited to basic research due to a lack of 
funding. 
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